RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Newton A. C. S. Wong; David Gonzalez; Manuel Salto-Tellez; Rachel Butler; Salvador J. Diaz-Cano; Mohammad Ilyas; William Newman; Emily Shaw; Philippe Taniere; Shaun V. Walsh

doi:10.1136/jclinpath-2014-202467

RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Newton A. C. S. Wong (Lead / Corresponding author), David Gonzalez (Lead / Corresponding author), Manuel Salto-Tellez (Lead / Corresponding author), Rachel Butler, Salvador J. Diaz-Cano, Mohammad Ilyas, William Newman, Emily Shaw, Philippe Taniere, Shaun V. Walsh

Research output: Contribution to journal › Article › peer-review

69 Citations (Scopus)

Abstract

Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.

Original language	English
Pages (from-to)	751-757
Number of pages	7
Journal	Journal of Clinical Pathology
Volume	67
Issue number	9
Early online date	4 Jul 2014
DOIs	https://doi.org/10.1136/jclinpath-2014-202467
Publication status	Published - Sept 2014

Access to Document

10.1136/jclinpath-2014-202467

http://jcp.bmj.com/content/67/9/751

Cite this

Wong, N. A. C. S., Gonzalez, D., Salto-Tellez, M., Butler, R., Diaz-Cano, S. J., Ilyas, M., Newman, W., Shaw, E., Taniere, P., & Walsh, S. V. (2014). RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. Journal of Clinical Pathology, 67(9), 751-757. https://doi.org/10.1136/jclinpath-2014-202467

@article{670f013928c644d7b25d5e2c66f8206e,

title = "RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group",

abstract = "Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.",

author = "Wong, {Newton A. C. S.} and David Gonzalez and Manuel Salto-Tellez and Rachel Butler and Diaz-Cano, {Salvador J.} and Mohammad Ilyas and William Newman and Emily Shaw and Philippe Taniere and Walsh, {Shaun V.}",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",

year = "2014",

month = sep,

doi = "10.1136/jclinpath-2014-202467",

language = "English",

volume = "67",

pages = "751--757",

journal = "Journal of Clinical Pathology",

issn = "0021-9746",

publisher = "BMJ Publishing Group",

number = "9",

}

Wong, NACS, Gonzalez, D, Salto-Tellez, M, Butler, R, Diaz-Cano, SJ, Ilyas, M, Newman, W, Shaw, E, Taniere, P & Walsh, SV 2014, 'RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group', Journal of Clinical Pathology, vol. 67, no. 9, pp. 751-757. https://doi.org/10.1136/jclinpath-2014-202467

RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. / Wong, Newton A. C. S. (Lead / Corresponding author); Gonzalez, David (Lead / Corresponding author); Salto-Tellez, Manuel (Lead / Corresponding author) et al.
In: Journal of Clinical Pathology, Vol. 67, No. 9, 09.2014, p. 751-757.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - RAS testing of colorectal carcinoma

T2 - a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

AU - Wong, Newton A. C. S.

AU - Gonzalez, David

AU - Salto-Tellez, Manuel

AU - Butler, Rachel

AU - Diaz-Cano, Salvador J.

AU - Ilyas, Mohammad

AU - Newman, William

AU - Shaw, Emily

AU - Taniere, Philippe

AU - Walsh, Shaun V.

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2014/9

Y1 - 2014/9

N2 - Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.

AB - Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.

U2 - 10.1136/jclinpath-2014-202467

DO - 10.1136/jclinpath-2014-202467

M3 - Article

C2 - 24996433

SN - 0021-9746

VL - 67

SP - 751

EP - 757

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

IS - 9

ER -

RAS testing of colorectal carcinoma: a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Abstract

Access to Document

Fingerprint

Cite this